셀라토즈 테라퓨틱스의 소식과 정보
[2020.09.11] In this engaging interview facilitated by CMT Research Foundation CEO Susan Ruediger, Dr. Jaeseung Lim with Cellatoz discusses their research in CMT and what to expect moving forward.
Ho Jin Kim, MSc.
Senior Managing Director
Head of Research & Chief Technology Officer
Mr. Ho Jin Kim is head of Biology Research responsible for research and development of cell therapies at our company and has lots of experiences in cell culture with specialty in the process development of cell therapeutics. He served as a general manager and head of translation research team at CHABiotech R&D division and contributed to develop CHA Biotech’s extensive regenerative medicine pipelines. He is a member of Cell Therapy, International Society of Cell Therapy (ISCT), International Society for Stem Cell Research (ISSCR), and Asian Cell Therapy Organization (ACTO). He holds a bachelor’s and master’s degree and Ph.D diploma in biology from Soonchunhyang University.
Jaeseung Lim, Ph.D
Chief Executive Officer & Chief Science Officer
Educations
Careers
Sung-Chul Jung, MD, Ph.D
Professor of Department of Biochemistry
Dr. Sung-Chul Jung is a physician and a Professor of Department of Biochemistry, College of Medicine at Ewha Woman’s University and served as a director of Institute of Convergence Medicine at Ewha Woman’s University Medical Center. His research interests are therapeutic strategies (cell and gene therapies) for genetic diseases, molecular pathogenesis of inherited metabolic disease and sphingolipid metabolism and function on human health and disease. Dr. Jung and his research team have studied cell therapies using tonsil-derived MSC differentiated into Schwann cells and/or muscle cells.
Myung-Kwan Han, Ph.D
Professor of Department of Microbiology
Dr. Myung-Kwan Han is Professor of Department of Microbiology, School of Medicine at Chonbuk National University and served as a member of review board of National Research Foundation of Republic of Korea. He has been interested in studying regulation mechanisms of embryonic stem cell proliferation and differentiations as well as novel cellular functions of well-known molecules(e.g. insulin). He and his research team recently identified a novel ES-derived musculoskeletal stem cell with evident biological markers.
Akihiro Shimosaka, Ph.D
Chairperson, Asian Cellular Therapy Organization (ACTO)
Dr. Akihiro Shimosaka is a chairman of Asian Cellular Therapy Organization(ACTO) having served from 2010 and is a director of Research Foundation for Community Medicine in Japan. He is one of pioneer developing biotech business creating and operating Kirin-Amgen, a JV company between Kirin and Amgen for commercializing EPO, G-CSF and TPO in 1984. He had various positions and worked as business consultant in different companies including Genentech, Immunex, Dendreon, Anosys, Cerus, Miltenyi, Medarex etc. Furthermore, he has served as a chairman of International Society of Cell Therapy (ISCT) Regulatory Affairs.